RxDoctor Payments Data

Jennifer Davis, DO

Neurology · Maple Valley, WANPI 1831485846

Payments from drug & device makers

$20,728in general payments, 2019–2025

Across 232 payments — averaging $89.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$17K
  • AbbVie$596
  • Teva Pharmaceuticals USA, Inc.$485
  • Merz Pharmaceuticals, LLC$481
  • Acadia Pharmaceuticals Inc$339
  • Acorda Therapeutics, Inc$221
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$11,55056%
  • Travel & lodging$3,11815%
  • Food & beverage$5,25925%
  • Education$5022%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,728 in reported general payments places this provider in the 80th percentile of 418 neurology providers in Washington.

See all neurology providers in Washington

Medicare billing

Part B allowed, 2024
$255,124
Medicare patients
125
Services billed
29,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa47$75,385
BotoxOnabotulinumtoxina17$47,015
Carbidopa-LevodopaCarbidopa/Levodopa263$11,018
Carbidopa-Levodopa ErCarbidopa/Levodopa89$3,205
Ropinirole ErRopinirole Hcl23$2,585
Rasagiline Mesylate23$2,212
Gabapentin86$1,797
Midodrine Hcl21$1,448
Fluoxetine Hcl11$1,289
Trazodone Hcl40$1,176
RivastigmineRivastigmine Tartrate17$1,020
Ropinirole Hcl18$666
Memantine Hcl14$571
Propranolol Hcl29$520
Donepezil Hcl68$519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$88$75,38547 claims
AbbVieBotox$596$47,01517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 418 neurology providers in Washington.

Other neurology in Maple Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →